双重特异性抗体疗法

多重特异性的开发

1月12日～13日

在抗体疗法的领域，掀起因强化开发多重特异性之抗体的新波。抗体乃藉由同时与2个以上的标的分子结合而得以强化，尤其是在癌的免疫疗法等方面有极佳的治疗效果。此部会除检讨开发多重特异性、确保安定性和功效时面临的各种课题外，亦介绍现在进行开发中各种形态的多重特异性抗体。

会期中来自世界各地的研究人员针对抗体开发令人瞩目的成果交换意见，展望癌治疗应用真正改革医疗技术的可能性等。

重点研习会：该领域的最尖端技术

Treatment of ALL with BiTE Antibody Blinatumomab

Patrick A. Baeuerle, Ph.D., Professor for Immunology; CSO & Senior Vice President, Micromet, Inc.

Bispecific Antibody Therapeutics Made by Dock-and-Lock

David M. Goldenberg, M.D., President, Garden State Cancer Center; CSO & CMO, Immunomedics, Inc.

Trifunctional Antibodies: Combining Passive and Active Immunization for Cancer Therapy

Horst Lindhofer, Ph.D., Founder & CEO, TRION Pharma GmbH

双重特异性抗体飞跃性的进步

Transcytosis of the Blood Brain Barrier with Bispecific Antibody Therapeutics

J. Michael Elliott, Senior Research Associate, Genentech

Bispecific Digoxigenin-Binding Antibodies for Targeted Payload Delivery

Ulrich Brinkmann, Ph.D., Leader, Pharma Research and Early Development (pRED), Biologics Engineering, Roche Diagnostics GmbH

双重特异性设计的进化

CVX-241: A VEGF and Ang2 Targeting Bispecific CovX-Body

Venkata Ramana Doppalapudi, Ph.D., Associate Research Fellow, CovX, Biotherapeutic Division of Pfizer

Talk Title to be Announced

Kevin FitzGerald, Ph.D., M.B.A., CEO, f-star GmbH

多重特异性的开发和安全性的问题

Safety Challenges to the Development of Bispecific Antibodies

Rakesh Dixit, Ph.D., Vice President, Research & Development; Global Head, Biologics Safety Assessments, MedImmune

多重特异性治疗用蛋白质的生产

Talk Title to be Announced

Jan van de Winkel, Ph.D., CEO, Genmab AS

Anticalins and Beyond - Simple Manufacturing of Next Generation Multispecific Therapeutic Proteins

Laurent Audoly, Ph.D., CSO, Pieris AG